इसराइल - हिब्रू - Ministry of Health

salomon,levin & elstein ltd - meropenem as trihydrate 1000 mg - powder for solution for inj/inf - meropenem - meropenem teva is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meropenem teva has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.

इसराइल - हिब्रू - Ministry of Health

salomon,levin & elstein ltd - fluconazole 100 mg - capsules - fluconazole - cryptococcosis. - systemic candidiasis. - mucosal candidiasis. - vaginal candidiasis. - dermatomycosis.

इसराइल - हिब्रू - Ministry of Health

salomon,levin & elstein ltd - fluconazole 2 mg / 1 ml - solution for infusion - fluconazole - cryptococcosis, systemic candidiasis, mucosal candidiasis.

इसराइल - हिब्रू - Ministry of Health

salomon,levin & elstein ltd - methotrexate 1000 mg / 10 ml - solution for injection - methotrexate - antineoplastic chemotherapy.psoriasis. rheumatoid arthritis.

इसराइल - हिब्रू - Ministry of Health

salomon,levin & elstein ltd - fludarabine phosphate 50 mg / 2 ml - concentrate for solution for injection / infusion - fludarabine - palliative treatment of patients with cll refractory to other therapy. treatment of less malignant non-hodgkin lymphoma of stage 3 to 4 in patients who have not responded to standard therapy with at least one alkylating agent or in whom the disease progressed during or after standard therapy. fludarabine teva is indicated for the initial treatment of patients with b- cell chronic lymphocytic leukaemia (cll) or after first line therapy, in patients with sufficient bone marrow reserves.

इसराइल - हिब्रू - Ministry of Health

salomon,levin & elstein ltd - gemcitabine as hydrochloride 200 mg/vial - powder for solution for injection - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

इसराइल - हिब्रू - Ministry of Health

salomon,levin & elstein ltd - gemcitabine as hydrochloride 1000 mg/vial - powder for solution for injection - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

इसराइल - हिब्रू - Ministry of Health

salomon,levin & elstein ltd - paclitaxel - תרכיז להכנת תמיסה לאינפוזיה - paclitaxel 6 mg/ml - paclitaxel - paclitaxel - ovarian carcinoma : paclitaxel teva is indicated alone or in combination for the treatment of advanced carcinoma of the ovary. breast carcinoma : paclitaxel teva is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin - containing combination chemotherapy. paclitaxel teva is indicated for the treatment of metastatic breast cancer after failure of combination chemotherapy. prior therapy should have included an anthracycline unless clinically contraindicated. advanced non small cell lung cancer : paclitaxel teva associated with cisplatium is indicated for the treatment of non small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. kaposis sarcoma : paclitaxel teva is indicated in the second- line treatment of aid's related kaposi's sarcoma. gastric carcinoma : paclitaxel teva for the treatment of advanced gastric carcinoma.

इसराइल - हिब्रू - Ministry of Health

salomon,levin & elstein ltd - epirubicin hydrochloride 2 mg / 1 ml - solution for injection / infusion - epirubicin - for the treatment of wide spectrum of neoplastic diseases, including:- breast carcinoma- lung carcinoma - high doses- ovarian carcinoma- gastric carcinomas- soft tissue sarcoma- i.v. administration for the treatment of advanced bladder carcinoma- intravesical administration of epirubicin has been found to be beneficial in the treatment of superficial bladder carcinomas and in the prophylaxis of recurrences after transurethral resection.

इसराइल - हिब्रू - Ministry of Health

salomon,levin & elstein ltd - oxaliplatin 50 mg/vial - powder for solution for infusion - oxaliplatin - oxaliplatin in combination with 5- fluorouracil (5-fu) and folinic acid (fa) is indicated for : - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour. - treatment of metastatic colorectal cancer.